Lobe Sciences Ltd. (CVE:LOBE) | Finanzwire

Basculer en Français

11025	Companies
241667	Keywords
170142	Articles
130115	Press releases

Home
Companies
Lobe Sciences Ltd.

BRIEF

published on 09/15/2026 at 05:05, 4 days 10 hours ago

Lobe Sciences to Showcase Low-Dose Psilocin Data at Summit

Clinical Data Neuropsychiatric Summit L-130 Psilocin Low-dose Therapy Outpatient Use
PRESS RELEASE

published on 09/15/2026 at 05:00, 4 days 10 hours ago

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit
Dr. Frederick D. Sancilio to present 'Reimagining Psychedelic Therapeutics for Daily Outpatient Use' at the 9th Neuropsychiatric Drug Development Summit on September 16, featuring Phase 1a results for Conjugated Psilocin™ (L-130)

Conjugated Psilocin Lobe Sciences Ltd. Psychedelic Therapeutics Dr. Frederick D. Sancilio Neuropsychiatric Drug Development Summit
BRIEF

published on 09/01/2026 at 01:05, 18 days 14 hours ago

Lobe Sciences Ltd. Completes Private Placement Upsize

Private Placement Clinical Trials Biopharmaceutical Lobe Sciences Sickle Cell
PRESS RELEASE

published on 09/01/2026 at 01:00, 18 days 14 hours ago

Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement
Lobe Sciences Ltd. announces closure of second tranche of non-brokered private placement offering, raising $60,000 for therapeutic development programs

Private Placement Biopharmaceutical Company Therapeutic Development Lobe Sciences Ltd. S-100 Drug Candidate
BRIEF

published on 08/29/2026 at 01:05, 21 days 14 hours ago

Lobe Sciences Ltd. Upsizes Private Placement

Private Placement Biopharmaceutical Regulatory Approval Capital Raising S-100 Drug
PRESS RELEASE

published on 08/29/2026 at 01:00, 21 days 14 hours ago

Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement
Lobe Sciences Ltd. announces upsize to non-brokered private placement offering, intending to raise gross proceeds of $60,000 for advancing therapeutic programs. Proceeds to be used for S-100 drug candidate and subsidiary development

Private Placement Clinical Trials Lobe Sciences Ltd. Therapeutic Programs S-100 Drug Candidate
BRIEF

published on 08/28/2026 at 14:05, 22 days 1 hour ago

Lobe Sciences Appoints New CFO Amid Strategic Growth

Life Sciences Leadership Transition New CFO Lobe Sciences Psilocin Therapeutic
PRESS RELEASE

published on 08/28/2026 at 14:00, 22 days 1 hour ago

Lobe Sciences Expands Leadership Team with New CFO Appointment
Dr. David Kideckel, PhD, MBA, appointed as CFO of Lobe Sciences Ltd., bringing expertise in life sciences and capital markets. Mirza Rahimani transitions to Vice President of Finance

Chief Financial Officer Pharmaceutical Industry Lobe Sciences Ltd. Mirza Rahimani Dr. David Kideckel
BRIEF

published on 08/20/2026 at 14:05, 30 days 1 hour ago

Lobe Sciences Ltd. Concludes $2.1 Million Private Placement

Private Placement Clinical Trials Biopharmaceutical Lobe Sciences S-100 Candidate
PRESS RELEASE

published on 08/20/2026 at 14:00, 30 days 1 hour ago

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement
Lobe Sciences Ltd. announces closing of non-brokered private placement offering of Common Shares. Proceeds for working capital and therapeutic development programs including S-100 drug candidate

Common Shares Private Placement Offering Therapeutic Development Lobe Sciences Ltd. S-100 Drug Candidate

1 2 ... 8

Accesswire

Published on 09/19/2026 at 00:55, 14 hours 54 minutes ago

Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 23:50, 15 hours 59 minutes ago

Mako Mining Announces Equity Incentive Grants
Published on 09/18/2026 at 22:00, 17 hours 49 minutes ago

Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 19 hours 14 minutes ago

Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 1 day 1 hour ago

AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement

View all ACCESSWIRE

EQS Group

Published on 09/19/2026 at 13:15, 2 hours 34 minutes ago

Eurobattery Minerals AB has received information regarding court judgment and criminal suspicion concerning the CEO
Published on 09/19/2026 at 07:30, 8 hours 19 minutes ago

Hong Kong sets out initiatives to secure long-term development of pillar industries
Published on 09/18/2026 at 18:45, 21 hours 4 minutes ago

Holding(s) in Company
Published on 09/18/2026 at 18:44, 21 hours 5 minutes ago

EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:13, 21 hours 36 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS

Les Echos

Published on 09/18/2026 at 18:34, 21 hours 15 minutes ago

Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 17:45, 22 hours 4 minutes ago

Press Release_Carrefour Bond_September 2026
Published on 09/18/2026 at 17:45, 22 hours 4 minutes ago

Share buyback for cancellation
Published on 09/17/2026 at 17:40, 1 day 22 hours ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 20:46, 2 days 19 hours ago

LNA SANTE : 2026 First Half Results

View all LES ECHOS COMFI WIRE